SCHEMBL3547348

SCHEMBL3547348

CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)NOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
KLK7 P49862 1/20 0.57
NPC1 O15118 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
KDM4E B2RXH2 1/20 0.51
GFER P55789 1/20 0.50
CTRB1 P17538 1/20 0.50
KDM1A O60341 1/20 0.49
RCOR1 Q9UKL0 1/20 0.49
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C9 P11712 1/20 0.48
RAB9A P51151 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547345 1.00 KMT2A (0.58) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL3546934 0.93 MEN1 (0.50) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL3546930 0.93 MEN1 (0.50) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL4228972 0.85 KMT2A (0.59) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL4228978 0.85 KMT2A (0.59) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL4366597 0.84 ALDH1A1 (0.64) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL6508896 0.84 ALDH1A1 (0.64) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL5173012 0.84 ALDH1A1 (0.64) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL13745767 0.84 KMT2A (0.58) KMT2AMEN1KLK7NPC1NPSR1
SCHEMBL5494817 0.84 KMT2A (0.58) KMT2AMEN1KLK7NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE KMT2A 1078/4885MEN1 3834/4885KLK7 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.